Wells Fargo
CNTA

Wells Fargo’s Centessa Pharmaceuticals CNTA Stock Holding History

Wells Fargo’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$238K Buy
6,000
+2,613
+77% +$66.8K ﹤0.01% 4607
2025
Q4 		$84.7K Buy
3,387
+1,008
+42% +$25.5K ﹤0.01% 5442
2025
Q3 		$57.7K Buy
2,379
+2,229
+1,486% +$39.6K ﹤0.01% 5516
2025
Q2 		$1.97K Sell
150
-31,296
-100% -$397K ﹤0.01% 6217
2025
Q1 		$452K Buy
+31,446
New +$515K ﹤0.01% 4169
2024
Q3 		– Sell
-520
Closed -$4.7K – 6939
2024
Q2 		$4.7K Buy
+520
New +$4.93K ﹤0.01% 5883

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wells Fargo's CNTA Position: Q1 2026 in Review

Wells Fargo increased its Centessa Pharmaceuticals (CNTA) stake by 77% in Q1 2026, buying an estimated $66.8K and bringing the position to 6,000 shares worth $238K. The position accounts for ﹤0.01% of the portfolio, ranked #4607.

Wells Fargo first reported a position in CNTA in Q2 2024 and has held it in 6 quarters since. The position peaked at $452K in Q1 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Wells Fargo held 6,000 shares of Centessa Pharmaceuticals worth $238K as of Q1 2026.
  • Wells Fargo bought 2,613 Centessa Pharmaceuticals shares in Q1 2026, an estimated $66.8K.
  • Centessa Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4607 holding.
  • Wells Fargo first reported a position in Centessa Pharmaceuticals in Q2 2024 and has held it in 6 quarters since.
  • Wells Fargo's Centessa Pharmaceuticals position peaked at $452K in Q1 2025.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.